Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 0.00 0.00 0.00 0.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.5 1.0 4.5 2

Salvarx Share Discussion Threads

Showing 201 to 224 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
14/8/2018
07:21
I'd guess it's the fact it's in shares, listed in Canada, rather than in cash. Would love to claim some credit for SALV but am no longer a holder - well done those who are.
spectoacc
14/8/2018
07:17
Because the consideration is in Portage shares it will depend how well Portage sell the deal to their Investor base. If Portage shares go up on back of deal announcement then we could see much higher than 100p. The see thru value right now should be close to 180c
the stigologist
14/8/2018
07:17
good news today currently up 124% why not 250% (see rns)? " Consideration Shares valued at approximately US$75.8 million, representing a premium of over 250% to the current market valuation of SalvaRx*"
andrbea
14/8/2018
07:16
Am hoping some clever person is going to come on here soon and explain what the hell the announcement really means. Shares, consideration shares, demerger shares, 100% of 94%, premium 250%, 18 demerger shares of $1.80 each for every existing share, bonus based on CEO's inside leg measurement (I made that last one up).... Price appears to have gone up by 3p. Presumably therefore the value is in the mysterious 18 for 1 demerger shares that come later ? 08:19 EDIT the price is 90p now - ADVFN chart way off
dexdringle
14/8/2018
07:11
100p today no doubt.
blueball
14/8/2018
07:11
Just a bit ! I wonder if there is any chance of an alternative (higher) offer coming in? Let's face it this in an 'inside' job. They know the value of the portfolio. (seen talk of multiples of 100p before) so will any other entity want to get involved ?
the stigologist
14/8/2018
06:53
Excellent, should be a good day on here today
amrishbhim
14/8/2018
06:36
Explains the recent interest. Obviously something must have leaked but the stock was way undervalued so it was only a matter of time
the stigologist
14/8/2018
06:35
Highlights · Consideration Shares valued at approximately US$75.8 million, representing a premium of over 250% to the current market valuation of SalvaRx* · Shareholders who continue to hold SalvaRx shares will also receive 18 Demerger Shares (i.e. Portage shares) for every share in SalvaRx held on the Demerger Record Date, equivalent to approximately US$1.80* per SalvaRx share · Portage has existing interests in four promising biotech companies and cash resources of approximately US$7.3 million which will be used to fund the ongoing development of the portfolio of oncology assets owned by SalvaRx Limited
the stigologist
03/8/2018
10:58
Aim, totally illogical market with bizarre price movements
kristini2
03/8/2018
09:53
Some decently sized buys for SALV going through today. f
fillipe
23/7/2018
17:23
What a total disgrace !
dexdringle
23/7/2018
14:22
Delay; https://www.investegate.co.uk/salvarx-group-plc--salv-/rns/delay-in-iox-development-programme/201807231317384740V/ I guess the many folks have not picked up on the above. That's because none of the intermittent trades today is very large, but the drop is 21.45% and my guess is there is more selling to come. That's unless there has been a lot of leaky baling, price to today's RNS. f
fillipe
20/7/2018
12:53
Intensity Therapeutics Inc. ($2million investment, representing 8.5% equity) Intensity Therapeutics Inc. ("Intensity") has been working diligently to find suitable patients in order to test the safety of its lead product, INT230-6 in humans with refractory solid tumors. Intensity announced on 28 February 2018 that it had demonstrated the safety of INT230-6 in the first six patients with ovarian, head and neck, skin, and thyroid cancers who have received INT230-6 injected into tumors which are superficially palpable. This has enabled the study to recruit and treat patients who can receive injections to deep tumors via image guidance. Indeed, the first patient with cholangiocarcinoma has been treated. The study is designed to further examine the safety and utility in a variety of tumor types.
fig1
20/7/2018
12:15
There's some excitement around intensity Ther- what's our holding in that one ? anyone..
kristini2
20/7/2018
10:34
Good broker! f
fillipe
20/7/2018
10:32
While I'm on my computer much of the day my thanks are to the broker who phoned me to alert the 60/66 spread on Monday. It didn't last long and he got me 63 to sell.
bscuit
20/7/2018
10:16
Mmmm, it hasn't needed much selling to knock the share price off its perch and even today to drop the best bid to 47p, as I type. I'll be having a few more here if the fall continues into next week. f
fillipe
18/7/2018
20:14
i've never regretted top slicing an aim stock spiking , they nearly always retrace
kristini2
18/7/2018
20:06
Impeccable timing Kristini.
fig1
16/7/2018
09:48
i've top sliced and will try to hold the balance LT, this type of position could go 40x over a 10 year period, good luck bcuit
kristini2
16/7/2018
09:17
Broker suggestion and in placing, which with subscribed share income tax loss relief limited the downside.
bscuit
16/7/2018
08:50
CEO's Strategic Report In its third year of operations, SalvaRx has continued to execute on its strategy to grow its pipeline of products and help develop innovative medicines for the treatment of cancer. We have now formed five investments, and have built a pipeline of ten compounds. Intensity Therapeutics, in which we have an 8.5% interest, has its first programme in the clinic and iOx is poised to enter the clinic soon with its lead compound. These represent major milestones that de-risk the programs. A huge amount of effort by the various teams has enabled us to progress our projects to this point. iOx Therapeutics Limited (56.95% subsidiary undertaking) iOx Therapeutics Limited ("iOx") has been progressing its two products through preclinical development and manufacturing. IMM60, which is the lead program, is preparing to enter the clinic soon. To enable this initiation of human testing, iOx needs to satisfy the regulators that it can manufacture the product to specification and has the ability to qualify the batches produced to ensure consistency across each dose. Much work has been done to inspect the contract manufacturing facilities that make the active ingredient and the drug product. The team has developed the analytical methods to test the batches of drug that are coming off the production line and it has successfully scaled the manufacturing process. The iOx team believes all the required information will be in place shortly to allow for a regulatory submission this year. This also includes the animal safety study agreed upon by the Medicines and Health Regulatory Agency to enable determination of a safe dose for humans. In parallel, the PRECIOUS team, a consortium of academic experts from five leading European universities, continues to make progress in the development of our second product, IMM65. IMM65 starts with the above mentioned active ingredient in IMM60 which gets co-formulated with a tumor vaccine (NY-ESO). We have established a process to manufacture these particles for human use and the team is actively managing the workflow to also enable a clinical trial to start next year. iOx continues to prosecute and progress its patent applications in major markets. Additional patents covering liposomal formulation of its iNKT agonist (US patent 15/253,307, EU patent 2654779) have been issued. After the year end, iOx announced the placement of US$950,000 in the form of a convertible loan in order to fund the near term R&D activities. iOx is actively seeking partners and license opportunities. Intensity Therapeutics Inc. ($2million investment, representing 8.5% equity) Intensity Therapeutics Inc. ("Intensity") has been working diligently to find suitable patients in order to test the safety of its lead product, INT230-6 in humans with refractory solid tumors. Intensity announced on 28 February 2018 that it had demonstrated the safety of INT230-6 in the first six patients with ovarian, head and neck, skin, and thyroid cancers who have received INT230-6 injected into tumors which are superficially palpable. This has enabled the study to recruit and treat patients who can receive injections to deep tumors via image guidance. Indeed, the first patient with cholangiocarcinoma has been treated. The study is designed to further examine the safety and utility in a variety of tumor types
the stigologist
16/7/2018
08:48
i just sold a third at 60.8p- nice looks solid for more gains though here, Bsuit, what made you buy in here ?
kristini2
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
SALV
Salvarx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200121 15:15:23